ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.
|Articles|June 4, 2009
- ONCOLOGY Vol 23 No 7
- Volume 23
- Issue 7
FDA Fast-Tracks Talactoferrin/Sunitinib for Renal Cell Carcinoma
Agennix announced that talactoferrin alfa has been granted Fast Track designation by the FDA for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent).
Advertisement
Agennix announced that talactoferrin alfa has been granted Fast Track designation by the FDA for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent). The Fast Track program is designed to expedite the review of investigational drugs for the treatment of patients with serious or life-threatening diseases where there is an unmet medical need.
Articles in this issue
over 17 years ago
Prophylactic Central Lymph Node Dissection: Continued Controversyover 17 years ago
Music Therapyover 17 years ago
Is There a Role for LHRH Antagonists in Prostate Cancer?over 17 years ago
The Role of LHRH Antagonists in the Treatment of Prostate CancerAdvertisement
Related to this article
Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5